Cornerstone Pharmaceuticals Announces Positive Phase I Data for CPI-613 in Relapsed or Refractory AML Patients to be …

| November 6, 2014 | 0 Comments

CRANBURY, N.J. — Cornerstone Pharmaceuticals, Inc., a development stage company and leader in the growing field of cancer metabolism-based therapeutics, today announced positive data from an ongoing Phase …

More:
Cornerstone Pharmaceuticals Announces Positive Phase I Data for CPI-613 in Relapsed or Refractory AML Patients to be …

Tags: , , , , , ,

Category: Uncategorized

About the Author ()

Leave a Reply